A corporate healthcare firm launched during the pandemic is gearing up for additional multi-million-pound growth as the business evolves and expands beyond CV19.
Agilis Health, which has multiple facilities in Aberdeen and Teesside, has completed its second year of business with a seven-figure turnover and is on target for 50% growth in the coming 12 months.
With ambitious plans for Y4 and Y5, the business is set to further double in size as it eyes acquisitions in the private healthcare, business service, and laboratory markets.
Launched in 2020 initially focussing on CV19 PCR, antigen analysis, and the associated complexities of international travel, Agilis already completed its first acquisition earlier this year taking over RelyOn Nutec’s occupational health divisions in Aberdeen and Teesside in a six-figure deal.
The business now delivers a fully managed service on an international basis covering all aspects of occupational health, corporate health and wellbeing, as well as continuing to support CV19 requirements nationally and internationally.
In the past three months Agilis has signed up 12 new business client contracts in the corporate health and wellbeing space with the pipeline of new customers growing, and set to continue for the remainder of 2022, and beyond. A further six potential tender response opportunities are also being targeted in the oil and gas, maritime, renewables, chemical, and manufacturing industries.
Mike Eriksen, Agilis Health Chief Executive, said: “We are on target to achieve our planned profile switch to 80% business to business customers which is a move away from the retail, transactional focus during CV19, replacing this with long term commercial contract revenues. With a strong pipeline in the coming months and plans to complete more acquisitions, we are looking at internationalisation of our managed corporate health service across Mexico, Brazil, and the Middle East to support our client requirements.
“The first two years of the business have seen us evolve at pace, we’re now right where we should be, on target with our initial plan and expansion goals. The future growth and strength of the business is incredibly exciting as we develop and deliver our managed service expertise across the UK and internationally, adding real value to SMEs and multinational corporates in a variety of industries, as well as supporting the oil and gas industry with the energy transition.”
The business is also set to grow its pharmacy network across the UK, which is a health and wellbeing access point unique to Agilis Health as an Occupational Health provider, allowing pharmacies to offer Agilis Health products, health assessments, blood tests, CV19 tests and other services to the consumer market, whether a member of the public or as an employee.
Agilis, which currently has 15 employees and an additional 25 expert associates covering clinical governance, additional healthcare delivery, UKAS/ISO accreditation, legal and HR, ensures that personnel are fully compliant over and above local, national and international requirements.
In addition to a traditional occupational health service, Agilis delivers a full corporate health and wellbeing package on a managed service basis, including but not limited to travel health, drug and alcohol consultancy and screening, health surveillance, the full scope of work related and executive medicals, management referrals, and CV19 screening, along with guidance for mental health and stress related absence, some of which is linked simply to organisational, community and environment change.
The business will continue to grow and disrupt through clinically driven innovation and rapid adoption of new technologies to deliver highly responsive, best in class Occupational Health and wellbeing services to its customers and partners.